UK markets closed

VYNE Therapeutics Inc. (VYNE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0700+0.1100 (+3.72%)
At close: 04:00PM EDT
3.3300 +0.26 (+8.47%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9600
Open2.9800
Bid3.0100 x 100
Ask3.1100 x 100
Day's range2.8601 - 3.0900
52-week range1.6700 - 8.7300
Volume283,020
Avg. volume125,355
Market cap43.284M
Beta (5Y monthly)1.41
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

    BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & In

  • GlobeNewswire

    VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

    2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024Ended 2023 with $93.3 million of cash, cash equivalents, restricted cash and marketable securities, providing runway through the end of 2025 and multiple expected clinical milestones BRIDGEWATER, N.J., Feb. 29,

  • GlobeNewswire

    VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

    Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentati